Suma Krishnan Sells 25,000 Shares of Krystal Biotech (NASDAQ:KRYS) Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $263.21, for a total transaction of $6,580,250.00. Following the transaction, the insider owned 1,403,155 shares in the company, valued at approximately $369,324,427.55. The trade was a 1.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Krystal Biotech Stock Down 2.6%

Shares of NASDAQ:KRYS opened at $253.69 on Friday. The company’s fifty day moving average is $269.86 and its two-hundred day moving average is $218.80. Krystal Biotech, Inc. has a 12-month low of $122.80 and a 12-month high of $298.30. The company has a market cap of $7.42 billion, a P/E ratio of 37.04 and a beta of 0.49.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Tuesday, February 17th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.62 by $0.08. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%.The business had revenue of $107.11 million during the quarter, compared to analysts’ expectations of $105.30 million. Equities research analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Institutional Trading of Krystal Biotech

Several large investors have recently made changes to their positions in the stock. Seven Fleet Capital Management LP bought a new position in shares of Krystal Biotech in the 4th quarter valued at approximately $986,000. Pacer Advisors Inc. lifted its holdings in Krystal Biotech by 182.0% in the 4th quarter. Pacer Advisors Inc. now owns 1,712 shares of the company’s stock worth $422,000 after purchasing an additional 1,105 shares during the last quarter. Vident Advisory LLC boosted its position in Krystal Biotech by 5.4% during the fourth quarter. Vident Advisory LLC now owns 1,494 shares of the company’s stock worth $368,000 after purchasing an additional 76 shares during the period. EP Wealth Advisors LLC bought a new stake in Krystal Biotech during the fourth quarter worth approximately $455,000. Finally, Empowered Funds LLC acquired a new position in Krystal Biotech during the fourth quarter valued at approximately $212,000. Institutional investors own 86.29% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on KRYS. HC Wainwright reaffirmed a “buy” rating and set a $310.00 target price (up from $240.00) on shares of Krystal Biotech in a research note on Friday, January 9th. Jefferies Financial Group increased their price target on shares of Krystal Biotech from $310.00 to $371.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. Bank of America raised their price target on shares of Krystal Biotech from $288.00 to $318.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. TD Cowen reaffirmed a “buy” rating on shares of Krystal Biotech in a research report on Friday, January 9th. Finally, The Goldman Sachs Group upped their price objective on shares of Krystal Biotech from $206.00 to $327.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $326.25.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.